Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$160.39 USD
+0.34 (0.21%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $160.91 +0.52 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 281 - 300 ( 410 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Details from Phase II Trial of REGN727 and Plans for Phase III Released
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Details from Phase II Trial of REGN727 and Plans for Phase III Released
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Solid Quarter as Controls Costs and Sets Portfolio Priorities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Solid Quarter as Controls Costs and Sets Portfolio Priorities
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Results with PCSK9 Targeted Therapies Validate Target for ALNY
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Results with PCSK9 Targeted Therapies Validate Target for ALNY
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
European Patent Office Upholds Key Patent Behind Alnylam?s Intellectual Property
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
European Patent Office Upholds Key Patent Behind Alnylam?s Intellectual Property
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M